- Acorda Therapeutics, a drugmaker, plunged around 40% after patients died during the company’s Parkinson’s disease drug trial, according to Bloomberg’s Natasha Rausch.
- Seven patients in the trial, which was in the final stages, developed a severe infection called sepsis, and five died.
- The company said it would stop adding new patients to the trial.
- It said it has no hypothesis yet for how the patients died, but four of the patients that developed sepsis also developed a condition called agranulocytosis, where white-blood cells disappear from the body, which can be linked to the drug.
- Shares were up 50% for the year before the drop on Wednesday.
- Read Bloomberg’s full story here.
NOW WATCH: Money & Markets videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.